Exogenous ADA was initially used to treat immune deficiencies involving ADA dysfunction [11,56,57,58], but subsequent studies showed that enhanced ADA function was associated with an increased incidence of autoimmune disease [11,59] and that the suppression of aberrant ADA activity by ADA inhibitors has an anti-inflammatory effect [60,61]. This evidence concerns the gene ADA and Immunodeficiency.